Form 4: Charles River Laboratories Director Martin Mackay Boosts Stake with Equity Grants

Charles River Laboratories International, Inc. Director Martin Mackay reported the acquisition of common stock and stock options, primarily as compensation for director services, increasing his beneficial ownership in the company.

Summary

• Martin Mackay, a Director at Charles River Laboratories International, Inc. (CRL), reported transactions on May 21, 2025.
• He acquired 946 shares of common stock at a price of $134.98 per share, which are unvested restricted stock units.
• An additional 815 shares of common stock were acquired at $134.98 per share, granted in lieu of director service fees for the term commencing May 20, 2025; these are also restricted stock units.
• Both sets of restricted stock units (946 and 815 shares, totaling 1,761 shares) vest upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Mr. Mackay also acquired 2,076 stock options with an exercise price of $134.98 per share.
• These stock options become exercisable upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders, and are set to expire on May 21, 2035.
• Following these transactions, Mr. Mackay directly beneficially owns 14,292 shares of common stock and 2,076 derivative stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their beneficial ownership in the company, primarily through compensation-related equity grants, which aligns their interests with shareholders. This indicates confidence in the company's future.

Positives

• Director Martin Mackay increased his beneficial ownership in Charles River Laboratories through the acquisition of 1,761 shares of common stock and 2,076 stock options, aligning his interests with shareholders.
• The grant of 815 shares in lieu of director service fees indicates a commitment to equity-based compensation for board members, which is a common practice to incentivize long-term performance.

Future Outlook

The document primarily details past transactions and vesting schedules for future equity, but does not provide broader forward-looking statements or guidance on company performance.

Industry Context

This Form 4 filing reports an individual director's equity transactions and does not provide information on broader industry trends or competitive landscape. It reflects standard practice for director compensation involving equity grants in publicly traded companies within the life sciences or contract research organization (CRO) sector, where Charles River Laboratories operates.

Comparison to Industry Standards

• This document reports standard equity compensation for a director, which is a common practice across industries, including the life sciences and pharmaceutical services sector.
• Companies like LabCorp (LH) or IQVIA (IQV) also utilize equity-based compensation for their executives and directors to align their interests with shareholders.
• The specific value and structure (RSUs, options) are typical for director compensation packages, aiming to incentivize long-term commitment and performance.

Related Party Transactions

• The grant of 815 shares in lieu of director service fees can be considered a related party transaction as it involves compensation to a director.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased equity ownership.

Next Steps

• Vesting of 1,761 restricted stock units upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Exercisability of 2,076 stock options upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Recommendation

Keywords

Charles River Laboratories, CRL, Martin Mackay, SEC Form 4, Insider Transaction, Stock Acquisition, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership